Vetter wins the AbbVie TRIUMPH AWARD
Caption: Troy Carpenter (President Vetter Pharma International USA — third from right), Casie Thomas (US Key Account Manager), Martin Schwab (Customer Project Manager — second from left) and Alexander Osswald (Team Leader Central Planning — first from left) accepted the Award in a ceremony in April 2016 representing the Vetter project team. They are joined by AbbVie's Terry Simmons (Vice President of Procurement — second from right), and Jose Sevilla (Program Director — first from right).
Leading CDMO claims prestigious customer award from one of the top-20 biopharmaceutical companies.
AbbVie has awarded Vetter, a leading contract manufacturing and development organization (CDMO), the TRIUMPH AWARD for 2015. The award was granted for meeting AbbVie’s ‘predetermined high-level demands of service’. Vetter received this prestigious award as a contract manufacturer in the category Third-Party Manufacturers - Supplier of the Year. Recently, Vetter announced that the company won two other coveted awards, the WorldStar Award 2016 for its syringe closure system Vetter-Ject, and the 2016 CMO Leadership Award in four categories including, quality, capabilities, expertise, and compatibility.
The AbbVie TRIUMPH AWARD was created to acknowledge contract service companies whose efforts are ‘well-aligned with the company’s business strategy, and make an important contribution to AbbVie’s strategic vision on a long-term basis’. With this award, granted within a field of more than one thousand contractors, the company recognizes its top performing contract suppliers for efforts that consistently add measureable value, and regularly exceed best-in-class performance on behalf of AbbVie and patients who come to rely on their products. Vetter received this prestigious award as a contract manufacturer for 2015 in the category Third-Party Manufacturers — Supplier of the Year. This recognition was achieved by meeting the predetermined high-level demands of service AbbVie has come to expect that is ‘consistently above-average’.
“The winning of this award is especially significant for Vetter as it recognizes our continuing efforts to provide our customers a high-level of service, and it is particularly gratifying since it is from one of the world’s leading biopharmaceutical companies,” said Vetter Managing Director Peter Soelkner. “This award is a reflection of the value that Vetter brings to the biopharmaceutical industry, and consequently to patients worldwide, and is yet another affirmation that Vetter continues to exceed the expectations of our peers in areas of critical importance to their business.” In a speech honoring Vetter for the award, AbbVie highlighted the importance of the good partnership it has forged with Vetter, specifically noting the achievement of a high number of commercial batches, as well as the many project activities performed on the company’s behalf.
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.